Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration

Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration.

The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.

There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections.

Source: Pharmaceutical-Business-Review.


Leave a Reply

Protected by Comment Guard Pro